Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Prospective Patient Preference Study for BTKi Treatment Attributes in CLL and SLL” explored the factors influencing patient decision-making, revealing key treatment preferences and highlighting the importance of incorporating these insights into clinical practice when selecting BTK inhibitors for patients with CLL or SLL.
Video content above is prompted by the following:
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More
2 Commerce Drive
Cranbury, NJ 08512